Colon Cancer – Stage III

Sponsor: Easton Cooperative Group (ECOG)

Study:  A021502

Phase III

Randomized Trial of Standard chemotherapy alone or combined with atezolizumab as adjuvant Therapy for patients with stage III colon cancer and deficient DNA mismatch repair

Eligibility Criteria:

  • Histologically proven Stage III colon adenocarcinoma
  • Completely resected tumors
  • Entire tumor in colon
  • No residual of lymph node involvement or metastatic disease
  • No active autoimmune disease, including colitis, panhypopituitarism, adrenal insufficiency
  • No known active hepatitis B or C infection
  • No active pulmonary disease with hypoxia

To learn more about available clinical research trials contact:

Deborah Brunetti, RN, CRC
Hunterdon Regional Cancer Center – Research Department
2100 Wescott Drive
Flemington, NJ 08822
908-237-2330 option #3